Director John Strain buys 150,000 shares at $0.79; pre-2025 transaction history shows 100% 90-day win rate; stock down 84.7% from 52-week high.
Director John Strain purchased 150,000 shares at $0.79, growing his stake to 270,000 shares (+125.0% increase). Notably, this insider's single prior LESL transaction (buy on 2024-08-29) delivered a 90-day return of +1860.5%, exemplifying a well-timed entry pattern. His cross-ticker track record shows 1 prior open-market buy with identical 90-day performance (+1860.5%), yielding a 100% 90-day win rate. However, the company's fundamentals remain stressed: latest-quarter revenue of $177.1M is down 8.3% year-over-year, and the firm posted a $-51.3M net loss over its most recent full fiscal year, while the stock trades -84.7% from its 52-week high of $115.20. A cluster pattern is present—3 other insiders also bought within the past 14 days—though this reflects coordinated positioning rather than contrarian conviction. The discrepancy between the insider's proven timing ability at this ticker and the company's deteriorating financial trajectory warrants investor scrutiny.
Strain John purchases 120,000 LESL shares at $2.53 as stock down 69.4% from $163.60 52-week high; cluster buy pattern with 2 others in 14 days.
Strain John acquired 120,000 shares of Leslie's at $2.53 on 2024-08-29, establishing an initial position in the company. This purchase occurs amid significant price deterioration: the stock is -69.4% from its 52-week high of $163.60 and -56.3% over the past 90 days, suggesting material weakness. Notably, 2 other insiders also bought within the past 14 days, forming a cluster buy pattern that may reflect concurrent assessment of the stock's depressed valuation relative to recent trading history. The company maintains profitability with $60.6M net income on $569.6M quarterly revenue, though annual growth has contracted by 7.1%, indicating operational headwinds worth monitoring.
